Atossa Therapeutics (FRA:YAG2) Change In Other Working Capital : €0.04 Mil (TTM As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Atossa Therapeutics Change In Other Working Capital?

Atossa Therapeutics's Change In Other Working Capital for the quarter that ended in Mar. 2024 was €0.02 Mil. It means Atossa Therapeutics's Other Working Capital increased by €0.02 Mil from Dec. 2023 to Mar. 2024 .

Atossa Therapeutics's Change In Other Working Capital for the fiscal year that ended in Dec. 2023 was €0.08 Mil. It means Atossa Therapeutics's Other Working Capital increased by €0.08 Mil from Dec. 2022 to Dec. 2023 .

Atossa Therapeutics Change In Other Working Capital Historical Data

The historical data trend for Atossa Therapeutics's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atossa Therapeutics Change In Other Working Capital Chart

Atossa Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Other Working Capital

Get a 7-Day Free Trial

-0.02

-0.52

-0.45

-0.57

0.08

Atossa Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Other Working Capital	Get a 7-Day Free Trial															0.04	2.22	-1.61	-0.58	0.02

Atossa Therapeutics Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.04 Mil.

Atossa Therapeutics Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Atossa Therapeutics's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Atossa Therapeutics (FRA:YAG2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (FRA:YAG2) » Definitions » Change In Other Working Capital

Comparable Companies

Traded in Other Exchanges

ATOS:USA ATOS:Mexico YAG2:Germany

Address

107 Spring Street, Seattle, WA, USA, 98104

Website

https://www.atossatherapeutics.com

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Atossa Therapeutics (FRA:YAG2) Headlines

No Headlines